Yuen Chan, H. L., Lim, Y., Seto, W. K., Ning, Q., Agarwal, K., Janssen, H. L., Pan, C. O., Chuang, W. L., Izumi, N., Fung, S., , , Brunetto, M., Flaherty, J., Mo, S., Cheng, C., Lin, L., Gaggar, A., Subramanian, M., Marcellin, P., Gane, E., Hou, J., & Buti, M. (n.d.). iDDF2020-ABS-0061 Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB). Gut, 69, A75–A76. http://access.bl.uk/ark:/81055/vdc_100137793068.0x000049